Adding pembrolizumab (200 mg every 3 weeks), a humanized monoclonal PD-1 antibody, to cisplatin or carboplatin/paclitaxel with or without additional bevacizumab, a recombinant monoclonal antibody to human vascular endothelial-derived growth factor (VEGF), in patients with advanced cervical cancer and a positive PD-L1 status (combined positive score (CPS) ≥ 1) demonstrated a significant improvement in median OS (not reached vs. 16.3 months; HR 0.64; p = 0.0001) and median DFS (10.4 vs. 8.2 months; HR 0.62; p < 0.0001). Here, CD274 is linked to cervical cancer.